Abstract: Subarachnoid hemorrhage (SAH) is a hemorrhagic stroke with high mortality and morbidity. An animal model for SAH was established by directly injecting a hemolysate into the subarachnoid space of rats or mice. However, the in vitro applications of the hemolysate SAH model have not been reported, and the mechanisms remain unclear. In this study, we established an in vitro SAH model by treating cortical pyramidal neurons with hemolysate. Using this model, we assessed the effects of recombinant human brain-derived neurotrophic factor (rhBDNF) on hemolysate-induced cell death and related mechanisms. Cortical neurons were treated with 10 ng/mL or 100 ng/mL rhBDNF prior to application of hemolysate. Hemolysate treatment markedly increased cell loss, triggered apoptosis, and promoted the expression of caspase-8, caspase-9, and cleaved caspase-3. rhBDNF significantly inhibited hemolysate-induced cell loss, neuronal apoptosis, and expression of caspase-8, caspase-9, and cleaved caspase-3. Our data revealed a previously unrecognized protective activity of rhBDNF against hemolysate-induced cell death, potentially via regulation of caspase-9-, caspase-8-, and cleaved caspase-3-related apoptosis. This study implicates that hemolysate-induced cortical neuron death represents an important in vitro model of SAH.
Introduction
Subarachnoid hemorrhage (SAH) is a type of stroke characterized by spontaneous bleeding into the subarachnoid space following trauma. 1 SAH has a high morbidity and mortality, and approximately 25% of patients die immediately after hemorrhage. 2 Early brain injury (EBI) and cerebral vasospasm are two major complications of aneurismal SAH. 3, 4 Cerebral vasospasm was proposed to be the primary treatment target for SAH. However, the prognosis of vasospasm remains unsatisfactory, even with proper management. 5 Therefore, eliminating EBI is becoming an alternative therapy of choice for SAH. Several mechanisms are involved in the pathogenesis of EBI after SAH, including neuronal apoptosis. 6 Brain injury following SAH has been well modeled by applying hemolysate directly into the subarachnoid space. The mechanisms and signaling pathways involved have been well investigated. 7, 8 However, an effective in vitro model for SAH is not available.
Recombinant human brain-derived neurotrophic factor (rhBDNF) is a neurotrophin that binds to the high-affinity tropomyosin-related receptor kinase B (TrkB) receptor to regulate neurodevelopmental processes, including neuronal survival, neuronal differentiation, and synaptic plasticity. [9] [10] [11] Huang et al 12 showed that upregulation of 
Materials and methods cell culture
The Institutional Animal Care and Use Committee of Wuhan University approved this study, and the Guide for the Care and Use of Laboratory Animals were the protocols followed. Newborn C57BL/6 mice (1-3 days old) were purchased from the Animal Center of Wuhan University.
Cerebral cortex tissue was obtained from newborn C57BL/6 mice as previously described.
14 Briefly, cortical tissue was pooled, minced, and gently dissociated by mechanical trituration in Ca 2+ -and Mg
2+
-free Hank's Balanced Salt Solution and then digested in 0.025% trypsin for 20 min at 37°C. The reaction was terminated by mixing the suspension with Dulbecco's Modified Eagle's Medium (Gibco BRL, Grand Island, NY, USA) supplemented with 20% fetal bovine serum. After that, cells were filtered through a nylon mesh and pelleted by centrifugation. Cells were plated on 100 mm dishes (precoated with 0.01 mg/mL poly-l-lysine) at a density of 7.5×10 6 cells/dish in Neurobasal medium supplemented with 2% B27, 0.5 mM glutamine, 50 units/mL penicillin, and 50 μg/mL streptomycin. Cells were cultured at 37°C in a humidified incubator containing 5% CO 2 . Culture medium was replaced twice a week. Cell cultures were routinely observed under a phase contrast microscope.
Immunofluorescence
Cortical neurons were grown on 12 mm glass coverslips and washed with Dulbecco's phosphate-buffered saline (DPBS, pH 7.4) before fixation with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) for 15 min. Cells were permeablized in 0.1% Triton X-100 for 5 min and washed three times with DPBS for 5 min. Nonspecific binding sites were blocked with 10% normal goat serum for 1 h at room temperature. Cortical cells were incubated in a NeuN antibody (1:100; Millipore, Temecula, CA, USA) overnight at 4°C followed by incubation with an appropriate fluorophoreconjugated secondary antibody. The nucleus was stained with 4′,6-diamidino-2-phenylindole.
Preparation of hemolysate
Hemolysate was prepared from C57BL/6 mouse arterial blood as previously described. 15 Briefly, the erythrocytic fraction was removed from whole blood and lysed by freezing on dry ice for 10 min followed by complete thawing twice. Hemolysate was kept at −80°C until use.
cell density assay
Cell viability was determined by counting the number of adherent cells as described previously. 16 The cells were seeded at a density of 5×10 5 cells/well in 24-well plates. The cells were treated with hemolysate diluted in Neurobasal medium (1:10, 1:100, 1:200, 1:500, and 1:1,000) for 24 h. Then, cells were incubated with hemolysate (1:100) and BDNF (10 ng/mL and 100 ng/mL) for 24 h. Nonadherent cells were removed by two washes with PBS. Adherent cells were harvested by trypsinization. Cells were counted using a hemocytometer. Cell viability in experimental groups was normalized to controls.
hoechst 33342 staining
After treatment, cells were stained by Hoechst 33342. The stained cells were washed twice with PBS and imaged using a confocal laser microscope (Leica TCS SP5, Leica Biosystems, Wetzlar, Germany) with the following parameters: excitation: 340 nm and emission: 510 nm. 
Flow cytometry analysis

Western blotting
After treatment, cells were lysed in lysis buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 1 mM dithiothreitol, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 50 mM sodium fluoride, and 1 mM sodium vanadate). The lysate was incubated on ice for 30 min and then centrifuged at 12,000× g for 10 min at 4°C. The supernatant was collected, and the 
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human BDNF prevents neuronal apoptosis in sah protein concentration was determined using a BCA kit (Beyotime, Ningbo, China). Equal amounts of protein were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes. After blocking with 5% nonfat milk, membranes were incubated in the following primary antibodies overnight at 4°C: anti-GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anticaspase-9, anticaspase-8, and anticleaved caspase-3 (Cell Signaling Technology, Danvers, MA, USA). After three washes with PBS, membranes were labeled with specific horseradish peroxidase (HRP)-coupled secondary antibodies (antimouse IgG HRP or antirabbit IgG HRP). Protein bands were visualized by staining with a chemiluminescent substrate detection reagent. Grayscale analysis of target bands was performed using ImageJ software.
statistical analyses
Data were analyzed by SPSS v. 13.0 (SPSS Inc., IBM, Armonk, NY, USA). The data were presented as mean ± SD for at least three independent experiments. Statistical significance was analyzed by one-way analysis of variance, and a P-value of ,0.05 was considered to be statistically significant.
Results
rhBDNF promotes neuronal viability after hemolysate treatment
In this study, we established a novel in vitro model that mimics the clinical scenario caused by SAH. Cortical neuron growth is presented in Figure 1 , and cortical neurons were identified by positive NeuN staining ( Figure 1D ). Hemolysate treatment caused obvious cell loss in a dose-dependent manner, but not until 24 h after incubation, according to the cell viability assay. After treatment with different hemolysate concentrations (1:10, 1:100, 1:200, 1:500, and 1:1,000) for 24 h, cell numbers decreased to 50.33%, 57.67%, 80.67%, 83.33%, and 86.67%, respectively. Based on these findings, we selected a hemolysate concentration of 1:100 for subsequent experiments.
As shown in Figure 2 , 10 ng/mL rhBDNF mitigated hemolysate (1:100)-induced cell loss, but this was not significant (P.0.05). A high concentration of rhBDNF (100 ng/mL) significantly eliminated hemolysate-induced cell loss (Figure 2 ).
rhBDNF inhibits hemolysate-induced neuronal apoptosis
The effects of rhBDNF on primary cortical neuronal apoptosis induced by hemolysate were evaluated by Hoechst staining. As shown in Figure 3 , cell nuclei had regular contours and were round or oval in shape in control cells. In contrast, most hemolysate-exposed cells had condensed chromatin, nuclear shrinkage, and contained apoptotic bodies. Interestingly, 10 ng/mL or 100 ng/mL rhBDNF significantly improved these hemolysate-mediated effects.
To further confirm the effects of rhBDNF on hemolysateinduced neuronal apoptosis, we performed flow cytometry. Compared with controls, exposure to hemolysates for 48 h significantly triggered apoptosis in cortical neurons (Figure 4) . However, hemolysate-induced neuronal apoptosis was dramatically decreased by treatment with 10 ng/mL or 100 ng/mL rhBDNF. rhBDNF suppresses expression of caspase-9, caspase-8, and cleaved caspase-3
Caspase signaling pathways participate in cell apoptosis and are involved in SAH. 17 We measured the expression of caspase-9, caspase-8, and cleaved caspase-3 in primary cortical neurons. As shown in Figure 5 , caspase-9, caspase-8, and cleaved caspase-3 were significantly upregulated after hemolysate treatment. In contrast, 10 ng/mL and 100 ng/mL rhBDNF significantly decreased the expression of caspase-8, caspase-9, and cleaved caspase-3 in hemolysate-treated cortical neurons (vs hemolysate alone, P,0.05). 
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Discussion
Hemolysates have been widely used to generate animal models of SAH. 18, 19 In the present study, we demonstrated that hemolysate can also be used for in vitro cortical neuron models of SAH. Moreover, we revealed that rhBDNF prevents hemolysate-induced apoptosis in cortical neurons through caspase pathways.
Three in vivo models have been used for SAH research: endovascular puncture, blood injection into the cisterna magna, and cross forebay. 20 However, in vitro SAH models, such as stimulating glial cells with hemoglobin (Hb) 6, 21 or mimicking SAH with cytochrome oxidase, 22 are still under investigation. In this present study, we established an in vitro model of SAH by application of hemolysate, which sufficiently simulated the clinical pathophysiological processes of SAH observed in vivo. 18, 19 Hemolysate contains multiple components that affect cell survival. For example, Hb and ATP influence vascular cells and tissues in vitro. 23 A combination of Hb and a low-molecular-weight (,2 kDa) hemolysate fraction caused contraction of cerebral arteries. However, these components were also associated with neuronal apoptosis during EBI after SAH. 24 Nevertheless, more Our findings demonstrated that hemolysate treatment causes cortical neuron detachment in a dose-dependent manner. We also found that different concentrations of rhBDNF prevent hemolysate-induced cortical cell loss. Using this in vitro model, we confirmed the neuroprotective effects of BDNF. Protective effects of rhBDNF against SAH have not been reported, but BDNF is involved in the onset of SAH. BDNF polymorphisms predict a poor outcome in aneurysmal SAH patients. 25 Moreover, BDNF was activated after cysteamine or Figure 4 rhBDNF inhibits hemolysate-induced neuronal apoptosis as indicated by flow cytometry analysis. Notes: (A) control group, (B) hemolysate group, (C) rhBDNF 10 ng/ml group, (D) rhBDNF 100 ng/ml group, and (E) quantification of apoptosis. **P,0.01; *P,0.05. Bars represent the mean ± standard deviation (n=4 per group). Abbreviations: rhBDNF, recombinant human brain-derived neurotrophic factor; Pi, propidium iodide.
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human BDNF prevents neuronal apoptosis in sah N-acetyl serotonin derivative treatment in models of SAH. 25, 26 These data implicate the validity of our in vitro model, as well as the potential therapeutic effect of BDNF in SAH.
To identify the underlying mechanisms of rhBD-NF-mediated protection against hemolysate-induced cortical neuron loss, we examined apoptosis. We showed that hemolysate treatment elicited apoptosis in cortical neurons. Takeda et al 27 reported that BDNF protects human umbilical vein endothelial cells from tumor necrosis factor-α-induced apoptosis, and Xia et al 28 showed that BDNF inhibits apoptosis in rats following spinal cord hemisection. In agreement with these findings, we found that rhBDNF mitigated hemolysate-induced apoptosis in cortical neurons. rhBDNF reduced apoptosis at lower concentrations and prevented cell detachment at higher concentrations. Taken together, these results revealed that rhBDNF protects against neuronal apoptosis in a concentration-independent manner.
Caspases are closely related to the apoptosis of eukaryotic cells. 29 A total of 14 caspase family members have been found and can be divided into two categories. One category activates other caspases, and this category includes caspase-1, -2, -4, -5, -8, -9, and -10. The second category executes apoptosis and includes caspase-3, -6, -7, and -14.
30
The apoptosis inducers stimulate apoptosis through membrane death receptors and mitochondrial pathways ( Figure 6 ). 31 Caspase-8 expression is activated by death receptors when apoptosis signaling is induced. Caspase-9 facilitates mitochondria-related apoptosis after release of cytochrome C. Caspase-8 and caspase-9 activate caspase-3, which executes apoptosis. These caspases are representative components of apoptosis, so we examined their expression in our study. We observed upregulated expression of caspase-8, caspase-9, and cleaved caspase-3 in our in vitro model of SAH. These findings suggest that both death receptor and mitochondria-related pathways are involved in hemolysateinduced apoptosis of cortical neurons. As previously discussed, hemolysate contains multiple components, which elicit vascular contraction, or activate cell death receptors and mitochondria-related apoptosis pathways. In addition, we showed that BDNF prevented neuronal apoptosis by inhibiting caspase-3.
32,33
Conclusion
We established a novel in vitro model for SAH and showed that rhBDNF inhibits neuronal apoptosis after SAH, which may represent an underlying mechanism for its neuroprotective effect against SAH. BDNF-mediated neuroprotection may be related to the activation of caspase-9, caspase-8, and cleaved caspase-3. 
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